- Continued advancement of the International Burden of Disease in Rett Syndrome Study
- Oral presentation on findings from concept elicitation interviews with caregivers and
Milan, Italy & Morristown, N.J. – October 6, 2017 - Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel
Not for release, publication or distribution, directly or indirectly, in the United States of America, Canada, Japan or Australia
THIS IS A RESTRICTED COMMUNICATION AND YOU
Not for release, publication or distribution, directly or indirectly, in the United States of America, Canada, Japan or Australia
THIS IS A RESTRICTED COMMUNICATION AND YOU MUST
Not for release, publication or distribution, directly or indirectly, in the United States of America, Canada, Japan or Australia
THIS IS A RESTRICTED COMMUNICATION AND YOU MUST
Not for release, publication or distribution, directly or indirectly, in the United States of America, Canada, Japan or Australia
THIS IS A RESTRICTED COMMUNICATION AND YOU MUST
Milan, Italy – September 14, 2017 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients
XADAGO (safinamide) is a once-daily tablet for Parkinson’s disease patients as an add-on to levodopa/carbidopa who are experiencing “off” episodes, providing “on” time without
Recruitment for potentially pivotal study in patients suffering from Rett syndrome ongoing in the USA, Europe, Asia and Australia
Milan, Italy and Morristown, N.J., USA – May 17,
Milan, Italy, May 12, 2017 – Newron Pharmaceuticals S.p.A. (“Newron”, SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with
The information on the following pages may be made available in the United States. By clicking on the link below, you agree that you are in the United States.
